Corvel CorpCRVL

CorVel Corp’s latest 10-K shows revenue of $958.5 million for the year to 31 March 2026, net income of $110.3 million, and diluted EPS of $2.14, all while sitting on $233.1 million of cash and equivalents and generating $155.6 million of operating cash flow. The balance sheet looks sturdy-$643.0 million of assets versus $248.8 million of liabilities-but the company’s public face is a set of brightly lit product pages that feel closer to a premium stationery brand than a workers-compensation claims processor. (source: SEC EDGAR 10-K, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874866/000164124826000014/xslF345X06/edgardoc.xml)

CorVel markets four service lines-Advocacy 24/7 nurse triage, Clinical Solutions for recovery pathways, General Liability claims handling, and Ancillary Care coordination-each illustrated with stock photos of smiling professionals in neutral office settings. The marketing material promises immediate medical guidance, reduced exposure, and faster recoveries, but the evidence trail stops at the corporate brochures and the SEC filings rather than a single named customer cohort or outcome study. The company’s own product pages offer no audited metrics, no peer-reviewed trials, and no public data on claims-cycle times or cost savings beyond the usual marketing assurances. (source: CorVel product pages: Advocacy 24/7, https://www.corvel.com/services/workers-compensation/advocacy-24-7/; Clinical Solutions, https://www.corvel.com/services/workers-compensation/clinical-solutions/; General Liability, https://www.corvel.com/services/liability/general-liability/; Ancillary Care Solutions, https://www.corvel.com/services/workers-compensation/ancillary-care-solutions/)

The DEF 14A filed on 26 June 2026 reveals a board and executive team long on tenure and short on explicit claims-cycle or actuarial credentials. Bertels, the Vice President of Network Services since 2010, is credited with over 36 years in risk management, yet the proxy offers no evidence that this experience translates to measurable reductions in claims duration or indemnity spend. Meanwhile, the company’s capital expenditure ran to $45.4 million in the year, a sum that-when set against the $155.6 million of operating cash flow-raises questions about the return on physical assets in a business that outsources most of its network work. (source: CRVL DEF 14A, 2026-06-26, https://www.sec.gov/Archives/edgar/data/874866/000119312526285509/d27672ddef14a.htm)

For direct data on the company’s market plumbing, the SEC submissions JSON lists the primary exchange as Nasdaq Global Select, ticker CRVL, with 51.6 million diluted shares outstanding. The companyfacts JSON confirms the revenue, net income, and EPS figures cited above, but offers no further operational granularity on customer wins, churn, or contract pricing. The EDGAR filing index shows no 8-K disclosures since June 2026, indicating no material events beyond the routine 10-K and DEF 14A filings. (source: SEC EDGAR submissions JSON for CIK 0000874866, https://data.sec.gov/submissions/CIK0000874866.json; SEC EDGAR companyfacts JSON for CIK 0000874866, https://data.sec.gov/api/xbrl/companyfacts/CIK0000874866.json)

CorVel’s operating model is straightforward: it processes workers-compensation and liability claims, coordinates medical care pathways, and outsources much of the heavy lifting to external networks while keeping the customer interface and billing under its own roof. The financials show a cash-generative business with $155.6 million of operating cash flow, 24.3% net profit margins, and a clean balance sheet, but the public evidence stops at high-level metrics and marketing collateral. There is no audited breakdown of client retention, average claims value, or network utilisation rates in the filings, and the product pages provide no peer-reviewed outcomes data. Until CorVel publishes operational KPIs that are as detailed as its polished brochures, the market is left to trust the numbers without the operational colour. (source: SEC EDGAR 10-K, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874866/000164124826000014/xslF345X06/edgardoc.xml)